Abstract
Although surgery is considered the only treatment to offer patients with localized pancreatic adenocarcinoma a chance of cure, resection alone is rarely sufficient for long-term survival. High rates of postoperative recurrence and subsequent disease-related mortality have, over the past two decades, encouraged the study and use of multimodality strategies that include adjuvant systemic chemotherapy and radiation. These modalities have been utilized both preoperatively and postoperatively with encouraging results. Moreover, their use has led increasingly to the development of institutional multidisciplinary groups with a focused interest in the care of patients with pancreatic malignancy, which have become responsible for the diagnosis, staging, treatment, follow-up and study of these patients. We review the rationale for the use of and the outcomes that may be achieved through the use of a multidisciplinary approach to patients with resectable adenocarcinoma of the pancreatic head.
Original language | English (US) |
---|---|
Pages (from-to) | 1611-1621 |
Number of pages | 11 |
Journal | Expert review of anticancer therapy |
Volume | 8 |
Issue number | 10 |
DOIs | |
State | Published - 2008 |
Externally published | Yes |
Keywords
- Adjuvant therapy
- Borderline resectable
- Chemoradiation
- Chemotherapy
- Neoadjuvant therapy
- Pancreatic cancer
- Pancreaticoduodenectomy
- Resectable
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)